Source: Financial Modeling Prep · peers by sector/industry
Insider activity (SEC Form 4)
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Valuation
Trading at 8.3× sales vs its 8.8× historical median P/S.
Fair value ≈ $15.34 · price $14.49 today
Undervalued · 6% below
Loading valuation…
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$FOLD Equity Corporate Actions Alert #2026 - 273
Information Regarding the Merger of Amicus Therapeutics Inc. (FOLD)
https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-273
At a special meeting held on March 3, 2026, the shareholders of Amicus Therapeutics Inc. $FOLD approved the proposed merger with BioMarin Pharmaceutical Inc. $BMRN . The merger is tentatively scheduled to close prior to the market open on April 27, 2026. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on April 24, 2026. If the merger closes as anticipated, the stock will remain halted on the day of closing (April 27th) and will be suspended effective April 28, 2026.
FOLD shareholders will receive $14.50 for each share held.
$TARS valuation, analyst consensus & related revenue multiples versus actual M&A revenue multiples paid to acquire $FOLD & $APLS
Analysts project TARS to generate more revenues over the next 5 & 9 years than FOLD. FOLD was acquired for an enterprise value of $4.8B. Analysts project TARS to generate slightly lower revenues over the next 5 & 9 years than APLS. APLS was acquired for an enterprise value of $5.6B.
If analysts project TARS revenues to be in between FOLD & APLS, does that suggest TARS' hypothetical M&A enterprise value would be somewhere in between the 2.
TARS revenues generate higher gross margins than both FOLD & APLS. Does this suggest TARS would (again hypothetically) command a higher M&A exit multiple?
We're curious what genuine TARS investors believe.
$XBI $IBB
$TVTX Just a reminder, $FOLD sold to $BMRN for $4.8 billion a few months ago. Amicus had been around a while and had steady revs of about $630 million in 2025.
$TVTX already has over $400 annual sales from Filspari in it's full year since approval, with high growth trajectory in IgAN. Now that they'll be adding another FSGS (which is double the price because double the dose, as confirmed on the call), then this company could really take of to the 15-$20 Billion market cap area very quickly.
Congrats to all longs!
This is not investment advice because we have no idea what $SNDX might be worth in a hypothetical M&A exit.
The attachment compares SNDX 7-year (FY26-FY32) analyst consensus revenue ests against mgmt/BOD prepared 7-year revenue forecasts from 11 recent peer commercial-stage bio M&A exits.
Analysts forecast SNDX to generate more revenues over the next 7 years than CCXI & AAAP mgmt/BOD prepared revenue forecasts when they were acquired for enterprise values ("EV") of $3.7B & $3.9B, respectively. CCXI projected 91% gross margins where SNDX actual FY25 gross margins were 96%.
SWTX mgmt/BOD prepared revenue forecasts were ~20% higher than analysts forecast for SNDX (though @ lower gross margins). SWTX was acquired for an EV of $3.4B.
We do not know if SNDX analyst estimates are accurate nor credible.
We're curious what SNDX investors believe would consider an adequate M&A exit EV for SNDX using these data points (or any others)? Is $FOLD an absolute ceiling?
$INCY $XBI $IBB
@flanker30
@JFais
$BCRX analyst consensus revenue estimates versus $FOLD both as of 12/15/25 (4 days before FOLD announced its sale). Obviously BCRX revenue estimates have been revised since but these are both as of 12/15/25.
Analysts forecast FOLD (again at the time) to generate 5.8% more revenues over the 10 year FY25 - FY34 period. However, BCRX product sales generated roughly 8% more gross profit margin in FY25.
FOLD was acquired for an enterprise value of roughly $4.8B (FOLD's cash/debt was a wash).
For those investors who believe drugs like Galafold & Orladeyo are worth some multiple and/or NPV of projected sales, FOLD may be a good peer for guesstimating a BCRX exit valuation. FOLD's SG&A was $40MM higher in FY25. There are other differences investors should consider including the costs to complete Astria's trials. BCRX's FY25 R&D expense was roughly $40MM higher.
This is not investment advice. We have no idea what BCRX might be worth in a hypothetical M&A exit.
$XBI $IBB
$BCRX 10-year analyst consensus revenue estimates v. the like 10-year revenue forecasts prepared by the mgmt/BOD of 9 peer comm'l-stage bios when acquired
Analysts forecast BCRX to generate slightly more revenues than CCXI mgmt/BOD forecast when CCXI was acquired for an EV of $3.7B. By itself, does this suggest BCRX would be worth more in EV if (2 HUGE IFs) BCRX analyst revenue estimates were credible AND if BCRX was worth peer M&A multiples. What about Astria clinical trial expenses to meet forecasts
$FOLD mgmt/BOD forecast 10-year revenues roughly 5% higher than analysts forecast for BCRX. FOLD was acquired for an EV of ~$4.8B
We're curious if BCRX investors believe BCRX is therefore worth somewhere between $3.7 & $4.8B (on the highest end) in a M&A exit? Are BCRX analyst estimates credible? Are the comparisons "apples to apples"?
Also attached is a fully diluted BCRX cap table at $15 per share using BCRX's 12/31/25 cap table (excl FY26 stock activity).
We're probably wrong. TINIA
$ARDX Just find this interesting...Not suggesting that ARDX will play out in similar fashion but really speaks to Rabbs ability...
Rabb was appointed chair of $FOLD on 3/2024, stock was trading $11-$13. In Jan 2025, the stock was trading around $5 due to missing guidance and high expenses. After this, he prioritized the global launch and revenue growth of Galafold (for Fabry disease) and Pombiliti + Opfolda (for Pompe disease). These products achieved significant combined product revenues (approx. $599M in late 2025), making the company an attractive acquisition target. One of the fastest turnaround story that ended with a Buyout at $14.5 -- all cash.
